Drugs /

gonadotropin-releasing hormone analog

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.

Clinical Trials

View Clinical Trials for gonadotropin-releasing hormone analog

Gonadotropin-releasing hormone analog has been investigated in 18 clinical trials, of which 18 are open and 0 are closed. Of the trials investigating gonadotropin-releasing hormone analog, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 10 are phase 2 (10 open), 4 are phase 3 (4 open), and 1 is phase 4 (1 open).

ER Expression, ER Positive, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for gonadotropin-releasing hormone analog clinical trials.

Prostate adenocarcinoma, prostate carcinoma, and breast adenocarcinoma are the most common diseases being investigated in gonadotropin-releasing hormone analog clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Gonadotropin-Releasing Hormone Analog
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gonadotropin-releasing hormone analog and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
lhrh analogue, gnrh agonist, gonadotropin-releasing hormone analogue, lh-rh analogs, luteinizing hormone-releasing hormone analog, lh-rf analogue, luteinising hormone-releasing factor analogue, gonadotropin-releasing hormone analogue, gnrh analog, lh-rh analogs, gonadotrophin releasing hormone analogue, gn-rh analogue, gonadotrophin-releasing hormone analog, lhrh agonist, gonadotropin-releasing hormone agonist, gonadotropin-releasing hormone analog, lh/fsh-rf analogue, gonadotropin-releasing hormone analog (product), luteinizing hormone-releasing hormone agonist, gnrh analogue, gonadotropin-releasing hormone analog, lh/fsh-rh analogue, gonadotrophin-releasing hormone analogue, gonadotropin-releasing hormone agonist, lh-rh agonist
NCIT ID [1]:
C1910
SNOMED ID [1]:
C-78111

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.